Aaron founded Genomic Vision in 2005 and was appointed as the company’s President and Chief Executive Officer in May 2006. He also serves as Genomic Vision’s Chief Scientific Officer.
Aaron bring more than 20 years of scientific and management experience to Genomic Vision and is responsible for the overall planning and execution of the company’s operations. He also facilitates and coordinates research collaborations and licensing and business agreements between Genomic Vision and other industry leaders and supervises trademark and patent activities. Aaron co-discovered Molecular Combing and is a recognized authority on all aspects of this pioneering technology. His contribution to the field has been widely published in leading medical and business journals and he has authored more than 20 patents on Molecular Combing
Prior to Genomic Vision he spent 15 years at the Pasteur Institute in Paris where he was Head of the Genome Stability Unit. Aaron received the Jacques Monod prize from the Fondation de France (an award to young scientists who have made significant advances in the early years of their career). Formerly, he pursued post-doctoral research in Prof. Jean-Pierre Changeux’s laboratory, Pasteur Institute, Paris, where he was awarded a Human Frontier Science Fellowship. Aaron received his Ph.D. from the Weizmann Institute of Science, Israel in 1993.
With over 20 years of professional experience in the field of finance and biotechnology, Erwan Martin is a specialist in finance and corporate development.
He joined Genomic Vision is 2009 as Administrative and Financial Director, before being appointed Vice-President of Finance and Corporate Development in 2011.
Erwan Martin started his career as an analyst with Syndex, a firm specializing in audit and consultancy.
In 2000, he co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in pharmaceutical research. A member of the board and then General Manager and Administrative and Financial Director, he supervised the development of the company, in particular organising several funding rounds and mobilizing over €20 million in public grants.
Erwan Martin holds an MBA from the Warwick Business School (United Kingdom). He is also a graduate of the Ecole Supérieure de Commerce (ESC) in Toulouse.
A physicist with over ten years’ experience in the development complex optical instrumentation. She joined Genomic Vision in 2006 as a project manager for R&D Instrumentation, before taking responsibility for the Department of Technology & Innovation. Today, Yamina is in charge of designing and developing specific imaging technologies and automating the molecular biology process.
Yamina Ghomchi started her career in 1997 at the Meudon Observatory, as part of her doctoral thesis, as a research engineer in the Laboratory for space studies and astrophysics instrumentation (LESIA), where she helped to develop an instrument for the ESA Rosetta space mission. She then joined Atmel Grenoble, as a Test & Characterisation engineer, and worked as a consultant for Segime (Altran group) in the field of high-precision optical systems.
She is a graduate engineer from the ENSPS (Ecole Nationale Supérieure de Physique de Strasbourg) and a doctor of physics (Astrophysics and associated Instrumentations) of the University of Paris-VI.
Jonathan Hanley joined Genomic Vision in 2013. With over 20 years of professional experience in biotechnology and venture capital investment, he brings to the company a broad knowledge of the biotechnology and healthcare industries from a research, management and venture capital perspective.
A member of the R&D executive board at Genomic Vision, Jonathan supervises project delivery and technology transfer to clients and partners; as well as seeking new avenues for development and partnership.
Jonathan graduated from Portsmouth University with a degree in biology before completing a PhD in biophysics at University College London. He also holds an MBA from the Ecole Nationale des Ponts et Chaussées in Paris.
He started his career as a research scientist at CEA-Saclay in 1993, and then joined the private sector five years later working for Transgenomic Inc. as a product scientist. In 2000, he was recruited as Director of Functional Proteomics at Genodyssee, where he was responsible for the development strategy of protein biopharmaceuticals. In 2002, he joined the National Physics Laboratories (NPL-Serco), in London, to become Head of Biotechnology.
Jonathan completed a duel competence in biotechnology and finance, working as an Investment Manager and Biotechnology analyst at Amundi (formerly Société Générale Asset Management) from 2005 to 2011 investing in biotech and pharma.